Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
← catalyst calendarNCT07161388 · readout in 772 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
21
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-17 | actual | When the study began enrolling |
| Primary completion | 2028-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Limited Stage Small-Cell Lung Cancer
Primary outcome
what the primary-completion date above is the date OFrwPFS
measured From 3 months before enrolment to follow-up of up to 36 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed